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Regulation of mTOR Signaling 
by Semaphorin 3F-Neuropilin 2 
Interactions In Vitro and In Vivo
Hironao Nakayama1,2,3,4, Sarah Bruneau2,5, Nora Kochupurakkal2,5, Silvia Coma1,3, 
David M. Briscoe2,5,* & Michael Klagsbrun1,3,6,*
Semaphorin 3F (SEMA3F) provides neuronal guidance cues via its ability to bind neuropilin 2 (NRP2) 
and Plexin A family molecules. Recent studies indicate that SEMA3F has biological effects in other 
cell types, however its mechanism(s) of function is poorly understood. Here, we analyze SEMA3F-
NRP2 signaling responses in human endothelial, T cell and tumor cells using phosphokinase arrays, 
immunoprecipitation and Western blot analyses. Consistently, SEMA3F inhibits PI-3K and Akt 
activity, and responses are associated with the disruption of mTOR/rictor assembly and mTOR-
dependent activation of the RhoA GTPase. We also find that the expression of vascular endothelial 
growth factor, as well as mTOR-inducible cellular activation responses and cytoskeleton stability 
are inhibited by SEMA3F-NRP2 interactions in vitro. In vivo, local and systemic overproduction of 
SEMA3F reduces tumor growth in NRP2-expressing xenografts. Taken together, SEMA3F regulates 
mTOR signaling in diverse human cell types, suggesting that it has broad therapeutic implications.
Neuronal networking is regulated by the response of axonal growth cones to environmental cues, both 
positive and negative. For instance, cues elicited by netrin-1 are chemoattractive, whereas those dom-
inated by semaphorin 3F (SEMA3F) are chemorepulsive. These processes, known collectively as axon 
guidance, play an important role in the development of the central nervous system1,2. SEMA3F is a 
member of the class 3 semaphorins (SEMA3A-G), whose receptors are neuropilin 1 (NRP1), neuropilin 
2 (NRP2) and Plexins3,4. Recently, we have demonstrated that semaphorins are involved in vascular and 
tumor biology5,6 and an increasing body of data indicate that they regulate the immune response perti-
nent to tumor immunity7–10. In addition, they inhibit the migration of endothelial cells (EC) and tumor 
cells in vitro and attenuate tumor progression, metastasis and angiogenesis in vivo5,6. Nevertheless, the 
response of T cells, EC, smooth muscle cells and tumor cells to SEMA3F is poorly understood but func-
tional effects are characterized by regulatory responses including anti-migration, cytoskeleton collapse 
and loss of stress fibers5,6,11.
Our initial analysis of SEMA3F signaling mechanisms demonstrated that SEMA3F forms a complex 
with NRP2 and Plexin A1. This complex attracts the ABL2 tyrosine kinase, which activates p190RhoGAP, 
resulting in the inactivation of RhoA, a small GTPase that converts GTP to GDP, leading to depolymeri-
zation of F-actin and the loss of stress fibers with an associated diminished EC and tumor cell migratory 
response6. Gleevec (imatinib), an ABL2 tyrosine kinase inhibitor abrogates SEMA3-mediated loss of 
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stress fiber formation and motility in glioblastoma cells and EC12. H157 lung cancer cells stably trans-
fected with SEMA3F have reduced levels of phosphorylated Akt (S473), STAT3 and Erk13, and reduced 
Akt activity was associated with lower levels of expression of the angiogenic factor, vascular endothelial 
growth factor (VEGF)13.
While semaphorins and NRP-elicited responses may regulate multiple intracellular signaling path-
ways, a common feature is the inhibition of the phosphorylation of the Akt kinase2,13. This effect is 
highly suggestive that a major biological effect of semaphorin-induced signaling involves the inhibition 
of mTOR signaling. Indeed, a recent study demonstrated that invertebrate semaphorin-plexin interac-
tions may regulate TOR signaling in Caenorhabditis elegans (C. elegans), which is required for morpho-
logical changes in its epidermal cells14. mTOR is a serine/threonine kinase that exists as two distinct 
multiprotein complexes, composed of either mTOR, raptor and mLST8 (mTORC1)15,16, or mTOR, rictor, 
Sin1, protor and mLST8 (mTORC2)17–19. mTORC1 controls cell growth in part by phosphorylating S6K1 
and 4EBP1 and is a key regulator of protein translation20,21. mTORC2 mediates cell survival and activa-
tion by phosphorylating Akt22, serum/glucocorticoid-regulated kinase-1 (SGK1) and protein kinase C 
(PKC)α 18,23. There is great interest in targeting mTOR signaling pathways as a therapeutic for autoim-
mune disease, chronic inflammation and allograft rejection24–26 and as an adjunct to cancer therapy27. 
Nevertheless, little is reported on the effects of SEMA3F on this signaling pathway or in these disease 
processes despite widespread expression of its NRP2 receptor on human immune, epithelial and tumor 
cells5,6,28.
In this report, we show that SEMA3F interacts with NRP2 and Plexin A1 to reduce PI-3K activity, 
inhibit the assembly of mTORC2 and reduce downstream Akt signaling. We also show that SEMA3F may 
elicit anti-tumor and anti-angiogenic effects by inhibiting PI-3K activity and Akt-induced transactivation 
of VEGF, which is well established to function in tumorigenesis and chronic inflammation. Collectively, 
our studies define SEMA3F as a novel PI-3K/mTORC2 inhibitor in mammalian cells, indicating that it 
has broad biological effects and potential as a therapeutic to enhance the resolution of chronic disease.
Results
SEMA3F inhibits Akt, mTOR, and S6K phosphorylation. To determine the effect of SEMA3F on 
intracellular signaling responses, we initially profiled levels of phosphokinases in the NRP2-expressing 
human glioblastoma cell line U87MG. We found that SEMA3F inhibited the phosphorylation of a num-
ber of kinases, notably, Akt (T308 and S473), Erk (T202/Y204 and T185/Y187) and mTOR (S2448) 
(Fig. 1A and Supplementary Table 1), which was confirmed by Western blot analysis (Fig. 1B). A time 
course analysis further indicated that pAkt (T308 and S473), pmTOR and its downstream signaling 
(pS6K and pS6) were inhibited within 10–20 minutes of SEMA3F treatment, and this inhibitory effect 
persisted for greater than 60 minutes (Fig.  1C and Supplementary Fig. 1A). SEMA3F failed to inhibit 
pAkt, pS6K and pS6 in both NRP2 and Plexin A1-siRNA transfected cells, indicating that the regulatory 
effect of SEMA3F on Akt/mTOR activity requires interaction with NRP2/Plexin A1 complexes at the cell 
surface (Fig. 1D and Supplementary Fig. 1B). SEMA3F also inhibited Akt (S473) and S6K phosphoryla-
tion in several other cell lines expressing NRP2, including U251 glioblastoma cells, a melanocyte cell line, 
Jurkat T lymphocytes, and endothelial cells (Supplementary Fig. 1C,D). Using a standard ELISA-based 
assay29, we found that SEMA3F inhibited PI-3K activity in each cell line in a time dependent manner 
(Fig. 1E). In addition, pre-treatment of endothelial cells with SEMA3F (for 30 minutes) inhibited subse-
quent VEGF-induced PI-3K activation (Fig. 1E). These results indicate that SEMA3F-NRP2 interactions 
are regulatory to inhibit the activity of PI-3K-Akt/mTOR signaling.
SEMA3F primarily inhibits the assembly of mTORC2. mTORC1 and mTORC2 signaling is crit-
ical for cell metabolism30,31 as well as the differentiation, proliferation and survival of many normal cell 
types27,32–35. By immunoprecipitation, we found that SEMA3F inhibited the association between mTOR 
and both raptor and rictor (Fig.  2A), suggesting a biological effect on both mTORC1 and mTORC2 
respectively. Consistent with this observation, cells treated with SEMA3F for 60 minutes had reduced 
levels of pAkt (T308 and S473) and pS6K (vs. untreated cells, Fig. 2B, lane 1 vs. 4). To determine if its 
primary mode of function relates to the inhibition of mTORC1 vs. mTORC2, we initially pretreated 
cells with rapamycin (10 nM for 30 minutes to inhibit mTORC1) and subsequently cultured cells in the 
absence or presence of SEMA3F and rapamycin for another 60 minutes. Treatment with rapamycin alone 
(for 90 minutes) as a control resulted in a marked inhibition of pS6K, but an induction in the levels 
of pAkt (T308 and S473) by 1.9-fold (p < 0.001) and 2.0-fold (p < 0.01), respectively (Fig.  2B, lanes 
1 vs. 2 and Fig.  2C), as we and others previously reported36–38. In contrast, U87MG cells that were 
treated with rapamycin for 30 minutes and subsequently treated with SEMA3F and rapamycin for an 
additional 60 minutes had reduced levels of both pS6K and pAkt (Fig.  2B, lane 2 vs. 5). Of note, this 
effect of SEMA3F on the inhibition of pAkt expression was similar to that observed when cells are 
treated with the mTORC1/C2 inhibitor Torin 1 (Fig.  2B, lane 3 vs. 4). SEMA3F also inhibited pSGK1 
(S422) and pPKCα (S657, Fig.  1B and Supplementary Fig. 2A), other known targets of mTORC2 
activity23.
To further evaluate whether the primary target of SEMA3F is the mTORC2 complex, U87MG cells 
were transfected with 2DAkt, in which the T308 and S473 sites are mutated to encode a constitutively 
active form of the kinase36,37. Previously, we reported that overexpression of 2DAkt in EC resulted in 
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Figure 1. SEMA3F inhibits the phosphorylation of Akt, mTOR and S6K. A, U87MG cells untreated 
(control) or following treatment with SEMA3F (640 ng/ml) for 30 minutes. Cell lysates were evaluated by 
phosphoprotein kinase antibody array. The intensity of each dot/phosphoprotein was measured using Image 
J software, as shown in Supplementary Table 1. B, Results of the array were validated by Western blot 
analysis. C, U87MG cells were treated with SEMA3F (640 ng/ml) as a time course up to 60 minutes and were 
analyzed by Western blot. D, U87MG cells were transfected with a control siRNA or with a NRP2-specific 
siRNA (20 nM). After 48 hours, the cells were treated with SEMA3F (640 ng/ml) for 30 and 60 minutes and 
analyzed by Western blot. Panels B–D are representative of 3 independent experiments. E, U87MG, Jurkat 
and HUVEC cells were treated with SEMA3F (200, 600, 1800 ng/ml, bars from left to right) for 15 minutes 
(grey bars) or 30 minutes (black bars); as a positive control, HUVEC were treated with VEGF-A (25 ng/ml) 
for 15 and 30 minutes. In addition, HUVEC were pre-treated with SEMA3F (1800 ng/ml) or PBS as a control 
for 30 minutes and subsequently VEGF-A (25 ng/ml) was added to the culture for 15 and 30 minutes. PI-3K 
activity was analyzed by ELISA according to the manufacturer’s instructions. Data represent the mean ± SD 
of 3 experiments.
www.nature.com/scientificreports/
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mTORC1 activation/signaling, which was inhibited by rapamycin37. Similarly, transfection of 2DAkt was 
associated with induced levels of expression of pS6K and pS6 in U87MG cells vs. control transfectants 
(Fig. 2D, lane 1 vs. 4), but there was no change in expression following treatment of transfected cells with 
SEMA3F. However, SEMA3F reduced the level of pAkt (S473) in 2DAkt transfectants (Supplementary 
Fig. 2A) and by immunoprecipitation, the treatment of 2DAkt-transfected cells with SEMA3F inhibited 
mTOR/rictor interaction (Supplementary Fig. 2B). Together, these results demonstrate that SEMA3F/
NRP2/Plexin A1 interactions have a direct effect on mTORC2 assembly which results in the inhibition 
of mTORC2/Akt activity.
Figure 2. SEMA3F disrupts both mTORC1 and mTORC2 complex formation. A, U87MG cells were 
treated with SEMA3F (640 ng/ml) for 30 minutes and were subjected to immunoprecipitation and Western 
blot analysis with anti-mTOR, -raptor and -rictor as illustrated. B, U87MG cells were treated with rapamycin 
(10 nM) or Torin 1 (10 nM) for 30 minutes, prior to SEMA3F (640 ng/ml) treatment for 60 minutes; lysates 
were analyzed by Western blot. C, The right bar graphs represent densitometric analysis of the illustrated 
blot showing the fold change in intensity (mean ± SD) relative to the untreated control (*p < 0.01; 
**p < 0.001 vs. untreated control). D, U87MG cells were transiently transfected with a pcDNA3.1 empty 
vector or with constitutively active Akt (2DAkt). Cells were treated with SEMA3F (640 ng/ml) and lysates 
were analyzed by Western blot. All data are representative of 3 independent experiments.
www.nature.com/scientificreports/
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mTORC2 links SEMA3F biology with the F-actin cytoskeleton. We next wished to determine 
whether the inhibition of mTORC2 serves as an intermediary response to link SEMA3F activity with 
cytoskeletal collapse. U87MG cells were treated either with SEMA3F, rapamycin or Torin 1 for 30 min-
utes and the actin cytoskeleton was visualized using phalloidin staining. As we previously reported6, 
SEMA3F markedly inhibited stress fiber formation and cytoskeletal arrangement compared to untreated 
cells (Fig.  3A, p = 0.002). Moreover, a similar effect was observed in cells treated with the mTORC1/
C2 inhibitor Torin 1 (p = 0.01). In contrast, treatment with the mTORC1 inhibitor rapamycin failed to 
elicit any cytoskeletal changes (Fig. 3A; Supplementary Fig. 3). Also, while SEMA3F inhibited stress fiber 
formation by 90% in pcDNA3.1 control vector transfected cells, it had minimal effects in U87MG cells 
transfected with an mTOR overexpression construct (Fig. 3B). We interpret these findings to suggest that 
the effect of SEMA3F on stress fiber formation is not mediated via mTORC1. Consistent with this inter-
pretation, knockdown of raptor also had minimal effects on stress fiber formation and cytoskeleton col-
lapse (Fig. 3C). However, SEMA3F reduced stress fiber formation in raptor-siRNA treated cells (Fig. 3C); 
and notably, siRNA knockdown of rictor alone was sufficient to elicit collapse (p = 0.02). These data 
suggest that mTORC2 serves as an intermediary to modulate SEMA3F-inducible cytoskeletal collapse.
We next measured RhoA activity39 using the rhotekin pulldown assay in U87MG cells transfected 
with the mTOR overexpression construct (Fig. 3D). Consistent with our previous findings6, RhoA activ-
ity was suppressed by SEMA3F in control pcDNA3.1-transfected cells (by 88%), but activity was partially 
rescued in cells overexpressing mTOR (by 55%). In addition, using siRNAs (as above) we found that 
knockdown of rictor, but not raptor, attenuated RhoA activity (Fig. 3E). Collectively, these observations 
demonstrate that the inhibition of mTORC2 activity by SEMA3F/NRP2/Plexin A1 interactions is func-
tional to inactivate RhoA, which in turn leads to cytoskeleton collapse.
SEMA3F inhibits hypoxia-induced production of VEGF via the mTOR pathway. The local 
expression and regulation of VEGF is key to many physiological and pathological processes40,41. Our 
previous findings are suggestive that SEMA3F may also target the transcriptional activation of VEGF36,42. 
To test the effect of SEMA3F on the regulation of VEGF expression, U87MG cells were transfected 
with a full-length 2.6 kb VEGF promoter-luciferase construct and exposed to the hypoxia mimetic 
agent desferrioxamine (DFO) or hypoxia (1% O2). We found that treatment with DFO induced VEGF 
promoter activity (by 16-fold, p < 0.001), which was partially inhibited (43%, p < 0.005) by SEMA3F 
(pre-treatment for 30 minutes, Fig. 4A). VEGF promoter activity was also increased (as expected43) fol-
lowing 18 hours culture in 1% O2 (Fig. 4B); again VEGF promoter activity was reduced following treat-
ment with SEMA3F (44%, p < 0.05), but not to basal levels. To test the relative effect of SEMA3F on 
mTORC1/C2, we transiently co-transfected U87MG cells with our 2DAkt construct and the full length 
VEGF promoter reporter construct, and we cultured the cells in the absence or presence of SEMA3F. 
We found that SEMA3F failed to attenuate VEGF promoter activity in 2DAkt transfected cells following 
treatment with DFO (Fig. 4C). Finally, we measured the effect of SEMA3F on the secretion of VEGF into 
conditioned media (by ELISA) in the absence or presence of DFO. DFO markedly increased VEGF pro-
duction (by 160% compared to untreated cells, p < 0.001 (data not shown) and inducible VEGF protein 
secretion was significantly reduced by either SEMA3F, rapamycin (for 18 hours to target mTORC1/C2) 
or by Torin 1 (Fig. 4D, p < 0.01). Concomitant treatment of the cells with rapamycin and SEMA3F failed 
to further suppress VEGF production, but the combination of SEMA3F and Torin 1 slightly (but signifi-
cantly p < 0.05) inhibited VEGF levels as compared to SEMA3F or Torin 1 alone (Fig. 4D). Collectively, 
these findings indicate that SEMA3F suppresses inducible VEGF expression in part via the regulation 
of mTOR activity.
SEMA3F inhibits U87MG tumor growth and angiogenesis in vivo. To next evaluate the in 
vivo relevance of our signaling studies, we examined the effect of SEMA3F on tumor growth in a 
well-established xenograft model5,44,45. In one approach, parental U87MG cells or U87MG cells that 
were engineered to constitutively overexpress SEMA3F were implanted subcutaneously into nude mice 
(1 × 106/mouse); tumor size (mm3) was measured at the indicated time points over a period of 3 weeks. 
We found that tumor growth was essentially absent when SEMA3F-producing cells were implanted vs. 
parental cells (p < 0.0005, Fig.  5A). Furthermore, immunohistochemical analysis of CD31-expressing 
EC demonstrated numerous blood vessels in parental U87MG tumors (Fig.  5B); in contrast, capillar-
ies within the U87MG/SEMA3F-derived tumors were constricted and were without discernable lumens 
(Fig. 5B).
Our second approach involved the injection of 1 × 106 U87MG cells into the skin of nude mice, and 
after 2 days the mice received a single intravenous injection of adenovirus encoding human SEMA3F 
tagged with His (Ad-3F) or a control adenovirus (Ad-Cont). Injection of Ad-3F (1 × 109 pfu) into mice 
did not result in any toxicity over a 30-day period; mice gained weight and typical behavior was normal. 
Western blot analysis showed that the administration of Ad-3F resulted in high levels of SEMA3F pro-
duction in the liver (Fig. 5C), and by ELISA, SEMA3F levels were measureable in the serum. Circulating 
serum levels of SEMA3F protein peaked on day 8 following administration of adenovirus (day 10 post 
injection of tumor cells), and persisted until the end of the experiment on day 14 (average of 26 ng/
ml, n = 4). Thus, this approach enables circulating SEMA3F production to begin at a time after tumor 
growth has been established in the mouse. We found that tumor volume reached 400 mm3 by day 14 
www.nature.com/scientificreports/
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Figure 3. mTORC2 participates in SEMA3F-induced RhoA inactivation and loss of stress fibers. A, 
U87MG cells were treated with SEMA3F (640 ng/ml), rapamycin (10 nM) or Torin 1 (10 nM) for 30 minutes. 
Subsequently, cells were stained with Alexa Fluor 488 phalloidin and Hoechst 33342 to identify F-actin 
cytoskeleton stress fibers and cellular nuclei, respectively. Representative cellular staining of is shown in each 
panel; the bar graph shows the mean ± SD number of fibers/cell in an average of 3 independent experiments. 
The scale bar indicates 20 μ m. B, U87MG cells were transiently transfected with a pcDNA3.1 empty vector 
or with a wild type (WT) mTOR plasmid and after 18 hours were treated with SEMA3F (640 ng/ml) 
for 30 minutes. Cells were stained as described above in A. Representative cellular staining is shown; bar 
graph represents the number of fibers/cell (mean ± SD) from 3 independent experiments. C, U87MG cells 
were transfected with control siRNA or with raptor- or rictor-specific siRNAs (20 nM). After 48 hours, 
they were treated with SEMA3F for 30 minutes and stained with Alexa Fluor 488 phalloidin and Hoechst 
33342 as above. The number of stress fibers was evaluated in 3 independent experiments and shown as the 
mean ± SD. D, U87MG cells were transiently transfected with pcDNA3.1 empty vector or with our WT 
mTOR plasmid. After 18 hours, the cells were treated with SEMA3F (640 ng/ml) for 10 minutes and RhoA 
activity was evaluated. E, U87MG cells were transfected with control siRNA or with raptor- or rictor-specific 
siRNAs (20 nM), were treated with SEMA3F (640 ng/ml) for 10 minutes and RhoA activity was analyzed. 
In Panels D–E, the intensity of active RhoA was normalized to respective total RhoA; the numbers below 
each gel lane represent the fold-change in intensity relative to control. Panels D–E are representative of 3 
independent experiments.
www.nature.com/scientificreports/
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in Ad-Cont-treated mice, whereas tumor growth was minimal over a 14 days period in mice injected 
with Ad-3F (p < 0.0001, Fig.  5C). By immunostaining, there was a striking collapsed phenotype of 
CD31-expressing capillaries within tumors harvested from Ad-3F-treated mice and most blood vessel 
lumens did not appear patent (Fig.  5D). Furthermore, by Western blot analysis, we found that pAkt, 
Figure 4. SEMA3F suppresses VEGF through the inhibition of mTOR-Akt signals. A,B, U87MG 
cells were transiently co-transfected with a full-length human VEGF promoter luciferase plasmid and 
a pGL4.74[hRluc/TK] plasmid as an internal control. Cells were treated with SEMA3F (640 ng/ml for 
30 minutes) prior to the addition of DFO (250 μ M) or the culture of cells in a hypoxia chamber (1% 
O2). After 18 hours, VEGF promoter luciferase activity was analyzed. C, U87MG cells were transiently 
co-transfected with our VEGF promoter luciferase and pGL4.74[hRluc/TK] plasmids and with either a 
pcDNA3.1 empty vector or our constitutively active Akt (2DAkt). The cells were treated with SEMA3F for 
30 minutes prior to the addition of DFO. After 18 hours, VEGF promoter luciferase activity was analyzed. 
D, Parental U87MG cells were treated with SEMA3F, rapamycin (10 nM), Torin 1 (10 nM) alone or in 
combination as indicated for 30 minutes prior to the addition of DFO, and culture supernatants were 
collected after 18 hours; VEGF protein levels were analyzed by ELISA. In each panel data are representative 
of 3 independent experiments. Bar graphs represent the mean ± SD of n = 3 experiments performed in 
triplicate, *p < 0.01 vs. control.
www.nature.com/scientificreports/
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pmTOR and pS6K levels were suppressed in tumors following treatment with Ad-3F, as compared to 
Ad-Cont-treated mice (Fig. 5E). Thus, in two very different approaches, we find that SEMA3F admin-
istration (local and/or systemic) has similar anti-tumor and anti- angiogenesis effects by inhibiting the 
Akt/mTOR signaling pathway.
Discussion
In these studies, we define SEMA3F as a potent mTOR inhibitor, and we show that its effect is mediated 
through the inhibition of PI-3K activity and the assembly of mTOR/rictor and mTOR/raptor complexes. 
We also find that its functional effect is mediated via interactions with the NRP2-Plexin A1 receptors. 
The regulation of mTOR by SEMA3F was found in several cell types, including T cells, endothelial cells 
and tumor cell lines, all of which are well established to utilize this signaling pathway for cellular acti-
vation, differentiation and proliferation. Our findings are suggestive that SEMA3F biology is of broad 
relevance in many physiological and pathological conditions, including cancer and diseases associated 
with chronic inflammation including allograft rejection.
While much is known about the intracellular regulation of mTORC1, relatively little is known 
about the upstream regulation of mTORC2 activity. In C. elegans, it has been shown that invertebrate 
semaphorin-plexin interactions reduce the association of TOR with rictor but promote TOR/raptor asso-
ciation, resulting in mRNA translation through the 4EBP-eIF4F pathway14. Our studies indicate that 
SEMA3F serves as a unique soluble ligand to selectively target mTORC2 activity in mammalian cells and 
thus elicit pro-resolution following cellular activation. For example, we transfected our NRP2-expressing 
cell lines with 2DAkt to activate mTORC1; in this model, we found that SEMA3F had minimal effects 
on the association between mTOR and raptor (data not shown) or the phosphorylation/activation of 
S6K and S6. In addition, SEMA3F responses were notably different than those observed following short 
time-course rapamycin treatment, which is known to primarily target mTORC1. In contrast, in several 
assays, we found that the inhibitory effects of SEMA3F on cellular activation and cytoskeletal collapse 
were primarily mediated through its effect on mTORC2 and were similar to those observed following 
treatment with Torin 1 (a pharmacological inhibitor of mTORC1/C2).
Importantly, we also found that SEMA3F reduced PI-3K activity which is reported to function in the 
activation of mTORC246,47. It is thus likely that SEMA3F inactivates mTORC2 via upstream inhibition 
of PI-3K. Another related family member NRP1 binds and activates phosphatase and tensin homologue 
deleted on chromosome ten (PTEN)7, a negative regulator of PI-3K. We thus postulated that one mechanism 
may involve the recruitment of PTEN, which in turn serves as an intermediary to regulate PI-3K activity. 
Consistent with this possibility, we found that PTEN co-immunoprecipitated with NRP2 in human umbil-
ical vein EC (HUVEC, Supplementary Fig. 4A). Moreover, following siRNA transfection and knockdown 
of Plexin A1, by immunoprecipitation, PTEN maintained association with NRP2 (Supplementary Fig. 4B). 
Furthermore, SEMA3F failed to inhibit pAkt expression following siRNA knockdown of PTEN in 
HUVEC (Supplementary Fig. 4C). These findings are most suggestive that the recruitment of PTEN to 
NRP2 is in part mechanistic for its regulatory effects on PI-3K/Akt/mTOR signaling.
However, U87MG, U251 and Jurkat cells are reported to be relatively PTEN deficient48–50 (see 
Supplementary Fig. 1C), suggesting that SEMA3F may also elicit its regulatory response(s) via 
PTEN-independent mechanisms. Indeed, as expected, PTEN failed to co-immunoprecipitate with NRP2 
in U87MG cells (data not shown). To this end, we screened other adaptors with potential to mechanis-
tically link NRP2 signals with PI-3K activity. These include GIPC1 (GAIP/RGS19-interacting protein, 
also known as neuropilin-interacting protein or synectin, Supplementary Fig. 4D)51–53, other GIPC fam-
ily members52 and DEP domain containing mTOR interacting protein (DEPTOR)32,54. However, siRNA 
knockdown of these adaptors did not alter the regulatory effect of SEMA3F on pAkt expression (data not 
shown). We also evaluated crosstalk between the effects of SEMA3F on mTOR/Akt and MAPK signaling. 
The pharmacological MEK inhibitor U0126 did not modulate the regulatory effects of SEMA3F on levels 
of pAkt, indicating that the inhibitory effect of SEMA3F on Akt-mTOR signaling is MAPK-independent 
(Supplementary Fig. 4E). Thus, while SEMA3F-NRP2 interactions may recruit PTEN to regulate PI-3K 
and mTORC2 in primary cultures of normal cells, additional adaptors/kinases may also function in this 
response.
The semaphorin family of axonal guidance molecules, including SEMA3F, are well established to pro-
mote neuronal growth cone collapse that results from concomitant rearrangement of actin cytoskeletal 
stress fibers. SEMA3F is a potent inhibitor of tumor cell and EC adhesion, spreading and motility in 
vitro and in vivo5,6. In addition, SEMA3F does not induce apoptosis in U87MG cells within 24 hours6. 
In tumor and vascular endothelial cells, we previously observed that SEMA3F inactivates RhoA, thereby 
inhibiting cytoskeletal stress fiber formation6,12. In this report, we extend our signaling studies and 
demonstrate that mTORC2 is an intermediary in this response, and is indispensable for RhoA inacti-
vation. For example, we show that SEMA3F treatment results in cell collapse following transfection of 
cells with mTOR (to induce mTORC1), suggesting that this effect is either mTOR-independent and/or 
is associated with targeting of mTORC2. Consistent with an effect on mTORC2, siRNA knockdown of 
rictor or the treatment of U87MG cells with the mTORC2 inhibitor Torin 1 consistently reduced the 
number of stress fibers as observed following treatment with SEMA3F. Importantly, we also noted that 
SEMA3F further reduced stress fibers in rictor-siRNA treated cells, indicating that SEMA3F likely inac-
tivates RhoA in part via mTORC2 and in part via another mechanism such as the ABL2/p190RhoGAP 
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pathway as we previously described6 (Fig.  6). Although mTORC2 is reported to interact with the Rho 
GTPase family and mediate F-actin cytoskeleton re-organization18,55, our new findings indicate that this 
effect can be targeted through stimulation of NRP2-induced signals.
We previously reported that mTORC2-dependent activation of Akt functions in the transcription of 
VEGF in endothelial cells36. VEGF functions as a pro-angiogenesis factor to augment tumor growth, 
and as a leukocyte chemoattractant in association with chronic inflammation43. Since SEMA3F targets 
mTORC2 activity, we postulated that it regulates the inducible expression of VEGF. Indeed, we found 
Figure 5.  SEMA3F inhibits human tumor growth in xenografts in vivo. A, Parental U87MG cells (Mock)
and human SEMA3F stable clones (S3F) were implanted into nude mice subcutaneously (1 × 106 cells/
injection). The insert shows Western blot analysis of SEMA3F expression in each cell line. Tumor size was 
measured using a standard calipers at the indicated time points. Numbers in parentheses represent the 
number of animals in each group. B, Representative immunohistochemical anti-CD31 staining of tumors 
harvested after 24 days. C, U87MG cells (1 × 106 cells/injection) were administrated subcutaneously into 
nude mice. After 2 days, control (Ad-Cont) or human SEMA3F-His (Ad-3F)-recombinant adenovirus 
(1 × 109 pfu) were injected intravenously via the tail vein. Tumor size was measured using a standard calipers 
at the indicated time points. Numbers in parentheses represent the number of animals in each group. Mice 
were sacrificed on day 14. The insert shows SEMA3F expression within the liver (on day 14) by Western 
blot analysis using an anti-His antibody. D, Representative immunohistochemical staining of tumors with 
anti-CD31. E, Western blot analysis of Akt/mTOR signaling pathway within tumor samples. Panels B,D,E 
are representative results of 3 independent experiments.
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that SEMA3F markedly inhibits inducible VEGF expression via the inhibition of both mTORC2 and 
mTORC1. However, SEMA3F failed to inhibit the transactivation of VEGF following transfection of 
cells with the 2DAkt construct which induces mTORC1 activation. Also, treatment with either SEMA3F 
or rapamycin (long-term treatment to inhibit both mTORC1/C2) or the mTORC1/C2 inhibitor Torin 1 
resulted in a similar level of inhibition of VEGF expression in U87MG cells. There was no additional 
inhibitory effect of combined SEMA3F and rapamycin, suggesting that SEMA3F and rapamycin target 
the same signaling pathway. However, surprisingly SEMA3F partially augmented the inhibitory effect 
of Torin 1 on VEGF expression. This may suggest that the Torin 1 dose used in these studies was not 
sufficient to completely inhibit mTORC2, or alternatively, it is possible that Torin 1 uncovers additional 
SEMA3F-elicited regulatory mechanism(s). Of note, SEMA3F alone fails to inhibit VEGF expression 
to basal levels, yet it has been previously reported to inhibit VEGF-induced proliferation of EC56. 
Nevertheless these new findings suggest that this anti-VEGF effect of SEMA3F may be most significant 
for its biological effects in vivo, such as our past5,6 and current observations on tumor growth inhibition.
Overexpression of SEMA3F in tumor cells, such as lung, brain and breast cancer cells was previously 
reported to inhibit tumor development in xenograft mouse models5,13,44,45,57. In these studies, we used 
an adenovirus to evaluate the effects of high levels of circulating SEMA3F protein on tumor growth 
and angiogenesis after tumors have developed. Most notably, circulating SEMA3F markedly inhibited 
tumor growth and all neoangiogenic blood vessels within the growing tumors had a dramatic collapsed 
phenotype, which is consistent with known SEMA3F effects on the cytoskeleton that we observed in 
vitro6. In addition, lysates of tumors from SEMA3F-treated mice showed diminished levels of pAkt, 
pmTOR and pS6K, which is consistent with its effects in vitro. Therefore, in vivo SEMA3F is likely to 
have an impact on tumor growth via both the suppression of VEGF secretion and direct inhibition of 
Akt-mTOR signaling. Also, the marked inhibition of tumor growth obtained by two different approaches 
(local overexpression by the tumor and by systemic administration) confirms that SEMA3F is a potent 
mTOR inhibitor in vivo.
In conclusion, these findings demonstrate that SEMA3F-NRP2 interactions inhibit intracellular PI-3K 
activity, mTORC2-dependent signaling, RhoA activity and cytoskeletal stress fiber formation. SEMA3F 
also inhibits the inducible expression of VEGF at both the transcriptional and protein level in vitro, and 
it has powerful anti-tumor effects in vivo. We conclude that SEMA3F is a secreted physiological mTOR 
inhibitor that functions to promote resolution following cellular activation. Our findings suggest that 
SEMA3F has therapeutic potential, not only in tumor biology, but also for instance to target chronic 
immune-mediated diseases, allograft rejection and/or angiogenesis related pathology.
Figure 6. Schematic cartoon showing regulatory signaling pathways mediated by SEMA3F-NRP2/Plexin 
A1 interactions. SEMA3F binds to the NRP2-Plexin A1 complex and associates with PTEN to inactivate 
PI-3K and mTORC2/Akt-dependent signaling. Receptor-mediated signals may also inactivate mTORC2/Akt 
signaling via PTEN-independent mechanisms in tumor cell lines. Functionally, these regulatory/pro-resolution 
signals suppress cell proliferation, migration, cytoskeletal stress fiber rearrangement and cell survival. Our 
previous findings demonstrate that SEMA3F also inhibits cytoskeleton structure in part by inactivating RhoA 
through both the ABL2 kinase and p190RhoGAP6; the current studies show that the inactivation of RhoA 
and cytoskeletal stress fiber rearrangement is also mediated via the inhibition of mTORC2.
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Methods
Antibodies and reagents. The antibodies, rabbit monoclonal anti-phospho-Akt (Thr308) antibody 
(#2965); mouse monoclonal anti-phospho-Akt (Ser473) antibody (#4051); rabbit polyclonal anti-Akt 
antibody (#9272); rabbit polyclonal anti-phospho-Erk1/2 (Thr202/Tyr204) antibody (#9101); mouse 
monoclonal anti-Erk1/2 antibody (#4696); rabbit monoclonal anti-phospho-S6K (Thr389) antibody 
(#9234); rabbit monoclonal anti-S6K antibody (#2708); rabbit monoclonal anti-phospho-S6 (Ser235/236) 
antibody (#4856); mouse monoclonal anti-S6 antibody (#2317); rabbit monoclonal anti-phospho-mTOR 
(Ser2448) antibody (#5536); rabbit polyclonal anti-mTOR antibody (#2972); rabbit polyclonal anti-plexin 
A1 antibody (#3813); rabbit monoclonal anti-raptor antibody (#2280); rabbit monoclonal anti-RhoA 
antibody (#2117); rabbit monoclonal anti-PTEN antibody (#9188) were all purchased from Cell Signaling 
Technology (Danvers, MA). Goat polyclonal anti-phospho-SGK (S422, sc-16745); mouse monoclonal 
anti-NRP2 antibody (C-9, sc-13117); goat polyclonal anti-GIPC antibody (N-19, sc-9648) were purchased 
from Santa Cruz Biotechnology, Inc (Dallas, TX). Rabbit polyclonal anti-rictor antibody (A300-458A) 
was purchased from Bethyl Laboratories, Inc (Montgomery, TX), and mouse monoclonal anti-β -actin 
antibody (AC-15) was from Sigma-Aldrich (St. Louis, MO).
The VEGF-A (DVE00) ELISA kit was obtained from R&D Systems (Minneapolis, MN). The 
PI3-Kinase Activity ELISA (K-1000s) was purchased from Echelon Biosciences (Salt Lake City, UT). 
The mTOR inhibitors, rapamycin and Torin 1, were purchased from Lc Laboratories (Woburn, MA) and 
R&D Systems, respectively. Desferrioxamine (DFO) was purchased from Sigma-Aldrich, and the MEK 
inhibitor (U0126) was purchased from EMD-Millipore (Billerica, MA). Wild type (WT) mTOR vector 
was kindly provided to David M. Briscoe (by Dr. Robert T. Abraham, Pfizer Worldwide Research and 
Development, Oncology Research Unit)58. A VEGF promoter luciferase construct plasmid encoding the 
2.6 kb full-length human VEGF was kindly provided by Dr. Debabrata Mukhopadhyay (Mayo Clinic, 
Minneapolis, MN)59. pGL4.74[hRluc/TK] vector (Promega Madison, WI) was used as an internal control 
in luciferase assay.
Cell culture. U87MG and U251 human glioblastoma cells, kidney 293 cells and 293T cells, and Jurkat T 
lymphocytes were obtained from American Type Culture Collection (ATCC, Manassas, VA) and cultured 
in media containing 10% FBS (Denville Scientific, Inc., South Plainfield, NJ) and 1% L-glutamine/pen-
icillin G/streptomycin sulfate (1% GPS, Life Technologies) as recommended. HUVECs were purchased 
from Lonza (Walkersville, MD) and cultured in EBM2 medium supplemented with EGM2 SingleQuot. 
Human melanocytes (HEMn-LP, Life Technologies) were maintained with Medium 254 supplemented 
with Human Melanocyte Growth Supplement (Life Technologies) in a 5% CO2 incubator at 37 °C. For 
all hypoxia experiments, cells were cultured in a hypoxic chamber (Heracell, Thermo Scientific, Hudson, 
NH) in 1% O2 at 37 °C.
Human recombinant SEMA3F. A full-length, His-Myc-tagged human SEMA3F construct was trans-
fected into 293T cells using FuGENE HD Transfection Reagent (Roche, Basel, Switzerland). SEMA3F 
secreted into culture medium was purified on HiTrap HP Chelating columns (GE Healthcare Bio-Sciences 
Corp., Pittsburgh, PA)60.
Phospho-kinase array. The Human Phospho-Kinase Array Kit (ARY003) was obtained from R&D 
Systems. U87MG cells were treated with SEMA3F which was previously found to induce cytoskeletal 
collapse and inhibit RhoA activity6. We had previously treated U87MG cells with SEMA3F at 320 ng/
ml which was found to induce morphological changes and inhibit cell migration in U87MG cell and 
HUVEC. Consistent with these results, we find that SEMA3F (even at the lowest concentration 200 ng/
ml) inhibits pAkt and pS6K signaling (Supplementary Fig. 1D). However, in other cell types, we found 
this concentration to be suboptimal to suppress these signals. Thus, we optimized a concentration at 
640 ng/ml to analyze SEMA3F signaling pathways. Cell lysates were collected at 30 minutes after SEMA3F 
treatment and the levels of phospho-proteins were analyzed with this array, according to the manufac-
turer’s instructions.
Western blotting. Proteins within each sample were separated by SDS-PAGE and transferred to 
nitrocellulose membranes. The membranes were blocked with 4% skimmed milk in TBS-T (0.1% Tween 
20 in tris-buffered saline [TBS]) for 30 minutes, followed by incubation with the primary antibody. After 
washing with TBS-T, membranes were incubated with the appropriate horseradish peroxidase-conjugated 
secondary antibody, and immunoreactivity was detected by using ECL detection reagents.
Immunoprecipitation. Cell lysates were immunoprecipitated using an appropriate antibody at 4 °C 
overnight. Protein G-Sepharose 4 Fast Flow beads (GE Healthcare) were added to each sample, followed 
by mixing for 1 hour at 4 °C. The samples were dissolved in SDS sample buffer and boiled for 5 minutes.
F-actin staining. Cells were fixed with 4% paraformaldehyde (PFA) followed by permeabilization 
with 0.2% Triton X-100 in PBS. F-actin and nuclei were stained with Alexa Fluor 488 phalloidin and 
Hoechst 33342, respectively. Confocal images from 3–5 areas of each culture were reviewed and stress 
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fibers were counted in representative individual cells (~5/experiment) using standard methodology as 
described6.
RhoA activity. RhoA activity assays were measured by using the RhoA activation assay kit based on 
rhotekin pull-down, according to the manufacturer’s instructions (Cytoskeleton, Denver, CO).
RNA interference. Transfection of siRNA (20 nM) was performed with siLentFect Lipid Reagent 
(Bio-Rad, Hercules, CA), according to the manufacturer’s protocol. Control siRNA (Silencer Negative 
Control #2 siRNA) was purchased from Life Technologies. ON-TARGETplus Human NRP2 siRNA was 
purchased from Thermo Scientific (Hudson, NH), Plexin A1 (Hs_PLXNA1_3), rictor (Hs_RICTOR_5), 
PTEN (Hs_PTEN_6) and GIPC1 (Hs_RGS19IP1_1) siRNA from Qiagen (Valencia, CA), and Raptor 
siRNA (sc-44069) from Santa Cruz Biotechnology, Inc. (Dallas, TX). In general, siRNA transfection was 
performed for 48 hours prior to assays.
Transfection and Luciferase assay. U87MG cells were transiently transfected with plasmid con-
structs (pcDNA3.1, WT mTOR, 2DAkt, VEGF luciferase reporter plasmid or pGL4.74[hRluc/TK]) as 
indicated using Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer’s instruc-
tions. After 18 hours, cells were treated as outlined in each experimental design. VEGF promoter activity 
was analyzed using a Dual-Luciferase Reporter Assay System (Promega), and luciferase activity was 
normalized by Renilla luciferase as an internal control.
Adenovirus. Recombinant control (#000047A) and human SEMA3F-His (#129755A) adenovirus 
were purchased from Applied Biological Materials, Inc. (Richmond, Canada). Each adenovirus was 
amplified with 293 cells and purified using the Fast Trap Adenovirus Purification and Concentration 
Kit (EMD-Millipore). The adenovirus titer was determined by Adeno-X™ Rapid Titer Kit (Clontech 
Laboratories, Inc., Mountain View, CA). We obtained each adenovirus at titers greater than 1 × 1010 pfu/
ml.
Tumor xenograft model. Parental U87MG cells or human SEMA3F stable U87MG clones (1 × 106/
injection) were administrated into nude mice (male, 8–10 weeks of age) subcutaneously. In one model, 
tumor size was measured every 3–4 days using a standard calipers. Mice were sacrificed on day 24 and 
tumors were removed. In a second model, parental U87MG cells were administrated into nude mice 
subcutaneously. In pilot studies, we injected adenovirus encoding SEMA3F (Ad-3F) or a control ade-
novirus (Ad-Cont) intravenously via the tail vein 3 days prior to tumor cell injection (1 × 106 U87MG 
cells/injection); we observed that all tumors in the Ad-3F group failed to grow (data not shown). Thus, 
we revised our approach, and we delayed administration of Ad-3F until day 2 after the tumor injection, 
so that tumor growth was initiated prior to peak SEMA3F production in the circulation (~day 8–10 post 
administration, data not shown). Tumor size was measured every other day using a standard calipers, 
serum samples were collected from the tail vein at day 5 and 8 and mice were sacrificed on day 14 
when the tumor, the liver and serum samples were collected. Production of SEMA3F was confirmed by 
Western blot analysis of liver with anti-His/anti-SEMA3F antibodies and by analysis of serum level of 
SEMA3F using the human SEMA3F ELISA kit (MBS454602) from MyBioSource (San Diego, CA). All 
animal studies were performed with approval in accordance with the guidelines of the Animal Care and 
Use Committee, Boston Children’s Hospital, Boston, MA.
Immunohistochemistry. Paraffin-embedded sections were deparaffinized and activated with pro-
teinase K (36 μ g/ml) in 0.2 M Tris buffer (pH7.2) at 37 °C for 30 minutes and processed for immuno-
histochemical staining. Immunohistochemistry was performed with anti-mouse CD31 antibody (BD 
Biosciences, San Jose, CA), the VectaStain Kit (Vector, Burlingame, CA) and the Tyramide Signal 
Amplification (TSA) Biotin system (NEN Life Science Products, Boston, MA), according to the manu-
facturer’s instructions.
Statistical analysis. All assays were independently performed at least three times. The results are 
represented as mean ± standard deviation (SD). Groups were compared using the Student’s t test and 
p values < 0.05 were considered statistically significant.
References
1. Klagsbrun, M. & Eichmann, A. A role for axon guidance receptors and ligands in blood vessel development and tumor 
angiogenesis. Cytokine Growth Factor Rev 16, 535–548 (2005).
2. Neufeld, G. & Kessler, O. The semaphorins: versatile regulators of tumour progression and tumour angiogenesis. Nat Rev Cancer 
8, 632–645 (2008).
3. Giger, R. J., Urquhart, E. R., Gillespie, S. K., Levengood, D. V., Ginty, D. D. & Kolodkin, A. L. Neuropilin-2 is a receptor for 
semaphorin IV: insight into the structural basis of receptor function and specificity. Neuron 21, 1079–1092 (1998).
4. Takahashi, T. & Strittmatter, S. M. Plexina1 autoinhibition by the plexin sema domain. Neuron 29, 429–439 (2001).
5. Bielenberg, D. R. et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, 
nonmetastatic tumor phenotype. J Clin Invest 114, 1260–1271 (2004).
www.nature.com/scientificreports/
13Scientific RepoRts | 5:11789 | DOi: 10.1038/srep11789
6. Shimizu, A. et al. ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human 
glioma cells. J Biol Chem 283, 27230–27238 (2008).
7. Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 
252–256 (2013).
8. Hansen, W. et al. Neuropilin 1 deficiency on CD4+ Foxp3+ regulatory T cells impairs mouse melanoma growth. J Exp Med 209, 
2001–2016 (2012).
9. Kumanogoh, A. & Kikutani, H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat Rev 
Immunol 13, 802–814 (2013).
10. Weiss, J. M. et al. Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced 
Foxp3+ T reg cells. J Exp Med 209, 1723–1742, s1721 (2012).
11. Bielenberg, D. R. et al. Increased smooth muscle contractility in mice deficient for neuropilin 2. Am J Pathol 181, 548–559 (2012).
12. Procaccia, V., Nakayama, H., Shimizu, A. & Klagsbrun, M. Gleevec/imatinib, an ABL2 kinase inhibitor, protects tumor and 
endothelial cells from semaphorin-induced cytoskeleton collapse and loss of cell motility. Biochem Biophys Res Commun 448, 
134–138 (2014).
13. Potiron V. A. et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Res 67, 8708–8715 
(2007).
14. Nukazuka, A., Tamaki, S., Matsumoto, K., Oda, Y., Fujisawa, H. & Takagi, S. A shift of the TOR adaptor from Rictor towards 
Raptor by semaphorin in C. elegans. Nat Commun 2, 484 (2011).
15. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 
110, 163–175 (2002).
16. Sancak, Y. et al. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25, 903–915 (2007).
17. Pearce, L. R. et al. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405, 513–522 
(2007).
18. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway 
that regulates the cytoskeleton. Curr Biol 14, 1296–1302 (2004).
19. Yang, Q., Inoki, K., Ikenoue, T. & Guan, K. L. Identification of Sin1 as an essential TORC2 component required for complex 
formation and kinase activity. Genes Dev 20, 2820–2832 (2006).
20. Sarbassov, D. D., Ali, S. M. & Sabatini, D. M. Growing roles for the mTOR pathway. Curr Opin Cell Biol 17, 596–603 (2005).
21. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471–484 (2006).
22. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR 
complex. Science 307, 1098–1101 (2005).
23. Garcia-Martinez, J. M. & Alessi, D. R. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation 
of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J 416, 375–385 (2008).
24. Dormond, O., Dufour, M., Seto, T., Bruneau, S. & Briscoe, D. M. Targeting the intragraft microenvironment and the development 
of chronic allograft rejection. Hum Immunol 73, 1261–1268 (2012).
25. Gamper, C. J. & Powell, J. D. All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling 
pathways in T cells. Front Immunol 3, 312 (2012).
26. Powell, J. D. & Delgoffe, G. M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. 
Immunity 33, 301–311 (2010).
27. Phung, T. L. et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10, 
159–170 (2006).
28. Mendes-da-Cruz, D. A. et al. Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. PLoS One 9, 
e103405 (2014).
29. Flaxenburg, J. A., Melter, M., Lapchak, P. H., Briscoe, D. M. & Pal, S. The CD40-induced signaling pathway in endothelial cells 
resulting in the overexpression of vascular endothelial growth factor involves Ras and phosphatidylinositol 3-kinase. J Immunol 
172, 7503–7509 (2004).
30. Kang, S. A. et al. mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341, 1236566 
(2013).
31. Pollizzi, K. N. & Powell, J. D. Integrating canonical and metabolic signalling programmes in the regulation of T cell responses. 
Nat Rev Immunol 14, 435–446 (2014).
32. Bruneau, S., Nakayama, H., Woda, C. B., Flynn, E. A. & Briscoe, D. M. DEPTOR regulates vascular endothelial cell activation 
and proinflammatory and angiogenic responses. Blood 122, 1833–1842 (2013).
33. Dazert, E. & Hall, M. N. mTOR signaling in disease. Curr Opin Cell Biol 23, 744–755 (2011).
34. Phung, T. L. et al. Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. 
Cancer Res 67, 5070–5075 (2007).
35. Shimobayashi, M. & Hall, M. N. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol 
Cell Biol 15, 155–162 (2014).
36. Dormond, O. et al. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of 
vascular endothelial growth factor in vitro and in vivo. J Immunol 181, 8088–8095 (2008).
37. Dormond, O., Madsen, J. C. & Briscoe, D. M. The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular 
endothelial cells. J Biol Chem 282, 23679–23686 (2007).
38. Zhang, H. H., Lipovsky, A. I., Dibble, C. C., Sahin, M. & Manning, B. D. S6K1 regulates GSK3 under conditions of mTOR-
dependent feedback inhibition of Akt. Mol Cell 24, 185–197 (2006).
39. Burridge, K. & Wennerberg, K. Rho and Rac take center stage. Cell 116, 167–179 (2004).
40. Carmeliet, P. & Jain, R. K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev 
Drug Discov 10, 417–427 (2011).
41. Ferrara, N. & Kerbel, R. S. Angiogenesis as a therapeutic target. Nature 438, 967–974 (2005).
42. Karar, J. & Maity, A. PI3K/AKT/mTOR Pathway in Angiogenesis. Front Mol Neurosci 4, 51 (2011).
43. Krock, B. L., Skuli, N. & Simon, M. C. Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117–1133 (2011).
44. Cao, Y. et al. Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Res 73, 
4579–4590 (2013).
45. Sabag, A. D., Bode, J., Fink, D., Kigel, B., Kugler, W. & Neufeld, G. Semaphorin-3D and semaphorin-3E inhibit the development 
of tumors from glioblastoma cells implanted in the cortex of the brain. PLoS One 7, e42912 (2012).
46. Gan, X., Wang, J., Su, B. & Wu, D. Evidence for direct activation of mTORC2 kinase activity by phosphatidylinositol 
3,4,5-trisphosphate. J Biol Chem 286, 10998–11002 (2011).
47. Zinzalla, V., Stracka, D., Oppliger, W. & Hall, M. N. Activation of mTORC2 by association with the ribosome. Cell 144, 757–768 
(2011).
48. Levitt, R. J., Georgescu, M. M. & Pollak, M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth 
factor binding protein-2. Biochem Biophys Res Commun 336, 1056–1061 (2005).
www.nature.com/scientificreports/
1 4Scientific RepoRts | 5:11789 | DOi: 10.1038/srep11789
49. Sakai, A., Thieblemont, C., Wellmann, A., Jaffe, E. S. & Raffeld, M. PTEN gene alterations in lymphoid neoplasms. Blood 92, 
3410–3415 (1998).
50. Wen, S. et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 98, 4622–4627 (2001).
51. Cai, H. & Reed, R. R. Cloning and characterization of neuropilin-1-interacting protein: a PSD-95/Dlg/ZO-1 domain-containing 
protein that interacts with the cytoplasmic domain of neuropilin-1. J Neurosci 19, 6519–6527 (1999).
52. Katoh, M. Functional proteomics, human genetics and cancer biology of GIPC family members. Exp Mol Med 45, e26 (2013).
53. Wang, L., Mukhopadhyay, D. & Xu, X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling 
during angiogenesis. Faseb j 20, 1513–1515 (2006).
54. Peterson, T. R. et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their 
survival. Cell 137, 873–886 (2009).
55. Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6, 
1122–1128 (2004).
56. Kessler, O. et al. Semaphorin-3F is an inhibitor of tumor angiogenesis. Cancer Res 64, 1008–1015 (2004).
57. Kigel, B., Varshavsky, A., Kessler, O. & Neufeld, G. Successful inhibition of tumor development by specific class-3 semaphorins 
is associated with expression of appropriate semaphorin receptors by tumor cells. PLoS One 3, e3287 (2008).
58. Sekulic, A. et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of 
rapamycin in mitogen-stimulated and transformed cells. Cancer Res 60, 3504–3513 (2000).
59. Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S. & Sukhatme, V. P. The von Hippel-Lindau tumor suppressor gene 
product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17, 5629–5639 (1997).
60. Bielenberg, D. R., Shimizu, A. & Klagsbrun, M. Semaphorin-induced cytoskeletal collapse and repulsion of endothelial cells. 
Methods Enzymol 443, 299–314 (2008).
Acknowledgments
We thank Evelyn A. Flynn for technical assistance with immunostaining of tissues, Kaifeng Liu 
for assistance with mouse studies and Drs. Diane R. Bielenberg, Calvin J. Kuo and Soumitro Pal for 
constructive and technical support. We also thank Melissa Anderson for support in editing of the 
manuscript. Funding: Research reported in this publication was supported in part by the Casey Lee Ball 
Foundation (to DMB) and by the National Institutes of Health under award number R01AI092305 (to 
DMB) and R56CA037392 (to MK). The content is solely the responsibility of the authors and does not 
necessarily represent the official views of the National Institutes of Health. HN received support from 
the Strategic Young Researcher Overseas Visiting Program for Accelerating Brain Circulation (No. S2207 
to Dr. Shigeki Higashiyama, Ehime University Proteo-Science Center) and a Postdoctoral Fellowship for 
Research Abroad from Japan Society for the Promotion of Science, Japan.
Author Contributions
Conception and design: H.N., S.B., D.M.B. and M.K.; Acquisition of data: H.N., N.K. and S.C.; Analysis and 
interpretation of data: H.N., S.B., N.K., S.C., D.M.B. and M.K.; Writing and review: H.N., D.M.B. and M.K.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Nakayama, H. et al. Regulation of mTOR Signaling by Semaphorin 
3F-Neuropilin 2 Interactions in vitro and in vivo. Sci. Rep. 5, 11789; doi: 10.1038/srep11789 (2015).
This work is licensed under a Creative Commons Attribution 4.0 International License. The 
images or other third party material in this article are included in the article’s Creative Com-
mons license, unless indicated otherwise in the credit line; if the material is not included under the 
Creative Commons license, users will need to obtain permission from the license holder to reproduce 
the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
